CytRx con­cedes that its on­ly drug flunked a PhI­II sar­co­ma test, rout­ing shares

Three years af­ter one of its drugs had to be scrapped fol­low­ing a failed study, CytRx was forced to con­cede that its Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.